In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications
Related Experiment Video
Updated: Jul 16, 2026
Spatial Measurements of Perfusion, Interstitial Fluid Pressure and Liposomes Accumulation in Solid Tumors
Published on: August 18, 2016
Jinzi Zheng1, Jubo Liu, Mike Dunne
1Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Purpose:
This study evaluated the in vivo performance of a liposome formulation that co-encapsulates iohexol and gadoteridol as a multimodal contrast agent for computed tomography (CT) and magnetic resonance (MR)-based image guidance applications.
Materials And Methods:
The pharmacokinetics and biodistribution studies were conducted in Balb-C mice using high performance liquid chromatography (HPLC) and inductively coupled plasma atomic emission spectrometry (ICP-AES) to detect iohexol and gadoteridol concentrations. The imaging efficacy of this liposome system was assessed in New Zealand White rabbits using a clinical CT and a clinical 1.5 Tesla MR scanner.
Results:
The vascular half-lives of the liposome encapsulated iohexol and gadoteridol in mice were found to be 18.4 +/- 2.4 and 18.1 +/- 5.1 h. When administered at the same dose the distribution (alpha phase) half-lives for the free contrast agents were 12.3 +/- 0.5 min (iohexol) and 7.6 +/- 0.9 min (gadoteridol); while, the elimination (beta phase) half-lives were 3.0 +/- 0.9 h for free iohexol and 3.0 +/- 1.3 h for free gadoteridol. The CT and MR signal increases were measured and correlated with the concentrations of iohexol and gadoteridol detected in plasma samples.
Conclusion:
The long in vivo circulation lifetime and simultaneous CT and MR signal enhancement provided by this liposome system make it a promising agent for image guidance applications.
